News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
55,941 Results
Type
Article (1283)
Company Profile (3)
Press Release (54655)
Section
Business (14786)
Career Advice (127)
Deals (3689)
Drug Delivery (8)
Drug Development (5182)
Employer Resources (8)
FDA (1420)
Job Trends (955)
News (25434)
Policy (1871)
Tag
Academia (137)
Accelerated approval (3)
Allergies (16)
Alliances (4463)
ALS (29)
Alzheimer's disease (142)
Antibody-drug conjugate (ADC) (48)
Approvals (1450)
Artificial intelligence (92)
Autoimmune disease (36)
Automation (6)
Bankruptcy (18)
Best Places to Work (809)
BIOSECURE Act (1)
Biosimilars (8)
Biotechnology (6)
Bladder cancer (20)
Brain cancer (6)
Breast cancer (46)
Cancer (533)
Cardiovascular disease (33)
Career advice (88)
CAR-T (54)
CDC (2)
Celiac Disease (1)
Cell therapy (121)
Cervical cancer (2)
Clinical research (4810)
Collaboration (183)
Compensation (89)
Complete response letters (9)
COVID-19 (139)
CRISPR (18)
C-suite (42)
Cystic fibrosis (25)
Data (783)
Denatured (2)
Depression (12)
Dermatology (11)
Diabetes (36)
Diagnostics (724)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (24)
Drug pricing (7)
Drug shortages (1)
Duchenne muscular dystrophy (16)
Earnings (7355)
Editorial (2)
Employer branding (2)
Employer resources (7)
Events (7497)
Executive appointments (43)
FDA (1793)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (6)
Funding (107)
Gene editing (29)
Generative AI (11)
Gene therapy (53)
GLP-1 (34)
Government (153)
Guidances (59)
Healthcare (1290)
HIV (1)
Huntington's disease (1)
IgA nephropathy (14)
Immunology and inflammation (27)
Immuno-oncology (12)
Indications (10)
Infectious disease (154)
Inflammatory bowel disease (8)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (30)
Interviews (13)
IPO (1811)
IRA (1)
Job creations (143)
Job search strategy (71)
JPM (3)
Labor market (1)
Layoffs (10)
Legal (364)
Liver cancer (5)
Longevity (2)
Lung cancer (74)
Lymphoma (57)
Machine learning (11)
Management (2)
Manufacturing (81)
MASH (17)
Medical device (1335)
Medtech (1343)
Mergers & acquisitions (2090)
Metabolic disorders (67)
mRNA (10)
Multiple sclerosis (36)
NASH (1)
Neurodegenerative disease (43)
Neuropsychiatric disorders (4)
Neuroscience (297)
NextGen: Class of 2026 (507)
Non-profit (210)
Now hiring (18)
Obesity (16)
Opinion (18)
Ovarian cancer (27)
Pain (20)
Pancreatic cancer (32)
Parkinson's disease (34)
Partnered (5)
Patents (75)
Patient recruitment (58)
Peanut (5)
People (3057)
Pharmaceutical (4)
Phase 1 (1457)
Phase 2 (2156)
Phase 3 (1589)
Pipeline (1081)
Policy (10)
Postmarket research (122)
Preclinical (652)
Press Release (1)
Prostate cancer (22)
Psychedelics (6)
Radiopharmaceuticals (16)
Rare diseases (108)
Real estate (362)
Recruiting (4)
Regulatory (1768)
Reports (4)
Research institute (112)
Resumes & cover letters (44)
Rett syndrome (7)
RNA editing (1)
RSV (1)
Schizophrenia (8)
Series A (14)
Series B (12)
Sickle cell disease (16)
Spinal muscular atrophy (10)
Sponsored (3)
Startups (217)
Stomach cancer (1)
Supply chain (6)
Tariffs (1)
Vaccines (47)
Venture capital (2)
Weight loss (5)
Women's health (6)
Worklife (1)
Date
Today (12)
Last 7 days (54)
Last 30 days (348)
Last 365 days (2742)
2026 (1317)
2025 (2629)
2024 (2976)
2023 (3245)
2022 (4290)
2021 (4688)
2020 (4254)
2019 (3373)
2018 (2732)
2017 (2355)
2016 (2178)
2015 (2908)
2014 (2054)
2013 (1714)
2012 (2120)
2011 (2289)
2010 (1985)
Location
Africa (48)
Alabama (7)
Arizona (13)
Arkansas (2)
Asia (2574)
Australia (574)
California (1193)
Canada (474)
China (83)
Colorado (57)
Connecticut (118)
Delaware (56)
Europe (5816)
Florida (183)
Georgia (21)
Idaho (3)
Illinois (101)
India (4)
Indiana (50)
Japan (32)
Kansas (42)
Kentucky (5)
Louisiana (8)
Maine (2)
Maryland (163)
Massachusetts (921)
Michigan (28)
Minnesota (39)
Mississippi (2)
Missouri (12)
Nebraska (2)
Nevada (8)
New Hampshire (18)
New Jersey (388)
New Mexico (2)
New York (230)
North Carolina (79)
North Dakota (2)
Northern California (639)
Ohio (42)
Oklahoma (1)
Oregon (3)
Pennsylvania (236)
Puerto Rico (1)
Rhode Island (5)
South America (53)
South Carolina (7)
Southern California (458)
Tennessee (11)
Texas (278)
United States (4286)
Utah (49)
Virginia (17)
Washington D.C. (3)
Washington State (86)
Wisconsin (17)
Wyoming (1)
55,941 Results for "insmed incorporated".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Insmed’s freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first full quarter of sales.
January 9, 2026
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed pointed to a strong placebo response as the reason for the trial’s failure.
December 19, 2025
·
2 min read
·
Tristan Manalac
Dermatology
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical and regulatory victories.
April 8, 2026
·
2 min read
·
Tristan Manalac
Approvals
Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker
Insmed’s Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the market.
August 13, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Insmed ‘Blows Away Expectations’ With Positive Data for Inhaled Hypertension Therapy
Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions TPIP to be best-in-class in pulmonary arterial hypertension.
June 11, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
April 1, 2026
·
3 min read
·
Nick Paul Taylor
Pharm Country
Insmed To Present at Three March Conferences
Insmed Incorporated today announced that management will present at the following investor conferences.
February 29, 2024
·
1 min read
Pharm Country
Insmed to Host Commercial Webinar on June 4, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company’s three most advanced programs, ARIKAYCE.
May 30, 2024
·
9 min read
Deals
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 3, 2024
Insmed Incorporated today announced the granting of inducement awards to 63 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee.
May 3, 2024
·
2 min read
Deals
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Insmed Incorporated today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share.
May 30, 2024
·
12 min read
1 of 5,595
Next
